company background image
1177 logo

Sino Biopharmaceutical SEHK:1177 Stock Report

Last Price

HK$2.75

Market Cap

HK$50.4b

7D

1.1%

1Y

-25.9%

Updated

18 Jun, 2024

Data

Company Financials +

Sino Biopharmaceutical Limited

SEHK:1177 Stock Report

Market Cap: HK$50.4b

1177 Stock Overview

An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.

1177 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance1/6
Financial Health5/6
Dividends3/6

Rewards

Risk Analysis

1177 passed our risk checks.

Sino Biopharmaceutical Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sino Biopharmaceutical
Historical stock prices
Current Share PriceHK$2.75
52 Week HighHK$3.89
52 Week LowHK$2.29
Beta0.58
1 Month Change-11.00%
3 Month Change-12.70%
1 Year Change-25.88%
3 Year Change-63.96%
5 Year Change-47.25%
Change since IPO10,025.93%

Recent News & Updates

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

May 21
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Recent updates

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

May 21
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20
Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Dec 18
Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Dec 02
Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

Nov 17
Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Aug 30
We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

May 26
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Apr 20
Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Feb 09
Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Nov 11
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Oct 24
Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Jul 08
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Apr 28
Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued

Jan 22
An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued

Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet

Dec 03
Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Oct 19
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02

Sep 03
Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02

Shareholder Returns

1177HK PharmaceuticalsHK Market
7D1.1%-2.8%-2.3%
1Y-25.9%-7.6%-3.6%

Return vs Industry: 1177 underperformed the Hong Kong Pharmaceuticals industry which returned -7.6% over the past year.

Return vs Market: 1177 underperformed the Hong Kong Market which returned -3.6% over the past year.

Price Volatility

Is 1177's price volatile compared to industry and market?
1177 volatility
1177 Average Weekly Movement5.9%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement7.2%
10% most volatile stocks in HK Market15.2%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 1177 has not had significant price volatility in the past 3 months.

Volatility Over Time: 1177's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200025,806Eric S. Y. Tsewww.sinobiopharm.com

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.

Sino Biopharmaceutical Limited Fundamentals Summary

How do Sino Biopharmaceutical's earnings and revenue compare to its market cap?
1177 fundamental statistics
Market capHK$50.43b
Earnings (TTM)HK$1.99b
Revenue (TTM)HK$28.19b

25.4x

P/E Ratio

1.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1177 income statement (TTM)
RevenueCN¥26.20b
Cost of RevenueCN¥4.99b
Gross ProfitCN¥21.21b
Other ExpensesCN¥19.36b
EarningsCN¥1.85b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.10
Gross Margin80.95%
Net Profit Margin7.05%
Debt/Equity Ratio32.3%

How did 1177 perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

46%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.